Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

• Status: Terminated
• Trial end date: 2019-03-19
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to compare clinical efficacy and tolerability of valproic acid (VPA) therapy versus dihydroergotamine (DHE) as abortive therapy in pediatric migraine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kimberly S Jones
• Treatments: Dihydroergotamine; Valproic Acid

Criteria

Inclusion Criteria:

• acute migraine as per ICHD-II criteria

• pediatric (age 10-18)

Exclusion Criteria:

For Valproic Acid (VPA)

• Pregnancy

• Liver disease (Acute or Chronic)

• Urea Cycle Disorder

• Mitochondrial Disease

For Dihydroergotamine (DHE)

• Pregnancy

• Peripheral vascular disease, coronary heart disease

• History of cerebrovascular event

• Severe or poorly controlled hypertension

• Impaired liver or renal function

• Triptan given in last 24 hours

• Hemiplegic migraine